XML 22 R8.htm IDEA: XBRL DOCUMENT v3.8.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Millions
12 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Mar. 31, 2016
Cash flows from operating activities:      
Net income $ 255.4 $ 164.6 $ 323.9
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation and amortization 615.9 469.2 283.2
Deferred income taxes 51.2 (126.9) (60.4)
Share-based compensation expense related to equity incentive plans 93.2 128.1 71.4
Excess tax benefit from share-based compensation 0.0 0.0 (0.8)
Loss on settlement of convertible debt 16.0 43.9 0.0
Amortization of debt discount on convertible debt 106.1 56.1 48.0
Amortization of debt issuance costs 6.6 4.5 4.0
Losses on equity method investments 0.2 0.2 0.3
Gains on sale of assets (5.9) (0.1) (1.0)
Loss on write-down of fixed assets 0.1 2.6 0.0
Impairment of intangible assets 0.5 11.9 0.6
Realized losses (gain) on available-for-sale investments 0.0 0.1 (13.7)
Realized gain on equity method investment 0.0 (0.4) (2.2)
Impairment of available-for-sale investment 15.5 1.4 4.0
Amortization of premium on available-for-sale investments 0.3 0.0 9.0
Changes in operating assets and liabilities, excluding impact of acquisitions:      
Increase in accounts receivable (85.3) (46.8) (2.1)
(Increase) decrease in inventories (59.2) 223.7 48.2
Increase in deferred income on shipments to distributors 41.0 109.4 17.0
Decrease in accounts payable and accrued liabilities (13.9) (14.8) (26.4)
Change in other assets and liabilities 14.0 25.7 0.1
Change in income tax payable 367.9 (2.2) 41.3
Operating cash flows related to discontinued operations 0.0 9.3 0.0
Net cash provided by operating activities 1,419.6 1,059.5 744.4
Cash flows from investing activities:      
Purchases of available-for-sale investments (1,594.8) (500.3) (1,573.9)
Maturities of available-for-sale investments 786.7 0.4 1,322.7
Sales of available-for-sale investments 0.0 470.2 1,501.5
Sale of equity method investment 0.0 1.7 2.7
Acquisition of Atmel, net of cash acquired 0.0 (2,747.5) 0.0
Acquisition of Micrel, net of cash acquired 0.0 0.0 (343.9)
Purchase of additional controlling interest in ISSC 0.0 0.0 (18.0)
Investments in other assets (7.1) (10.2) (7.1)
Proceeds from sale of assets 10.3 23.0 14.3
Capital expenditures (206.8) (75.3) (97.9)
Net cash (used in) provided by investing activities (1,011.7) (2,838.0) 800.4
Cash flows from financing activities:      
Payments on settlement of convertible debt (73.4) (436.2) 0.0
Proceeds from issuance of 2017 senior debt 0.0 2,070.0 0.0
Proceeds from issuance of 2017 junior debt 0.0 575.0 0.0
Repayments of revolving loan under credit facility (187.0) (2,781.0) (1,614.4)
Proceeds from borrowings on revolving loan under credit facility 187.0 1,537.0 2,204.5
Deferred financing costs (1.2) (36.9) (2.2)
Payment of cash dividends (337.5) (315.4) (291.1)
Repurchase of common stock 0.0 0.0 (363.8)
Proceeds from sale of common stock 42.0 42.2 28.7
Tax payments related to shares withheld for vested restricted stock units (44.4) (58.4) (21.7)
Capital lease payments (0.8) (0.8) (0.6)
Excess tax benefit from share-based compensation 0.0 0.0 0.7
Net cash (used in) provided by financing activities (415.3) 595.5 (59.9)
Effect of foreign exchange rate changes on cash and cash equivalents 0.0 (1.0) 0.0
Net (decrease) increase in cash and cash equivalents (7.4) (1,184.0) 1,484.9
Cash and cash equivalents at beginning of period 908.7 2,092.7 607.8
Cash and cash equivalents at end of period $ 901.3 $ 908.7 $ 2,092.7